William Blair analyst Tim Lugo downgraded Lyra Therapeutics (NASDAQ: LYRA) from Outperform to Market Perform.The analyst comments "With the disappointing ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE